Skip to main content
Premium Trial:

Request an Annual Quote

Proteomics International Snatches $1M Grant to Develop Kidney Disease Biomarkers for CDx

NEW YORK (GenomeWeb News) – The Australian government has awarded Proteomics International A$1 million (US$ 1 million) to develop biomarkers for diabetic kidney disease into a companion diagnostic test.

The funding from Commercialisation Australia — a merit-based, competitive assistance program — will be used by Perth, Australia-based Proteomics International to further validate its discovered biomarkers by performing additional analysis on patient groups. The work, the company said, should result in a more sensitive and effective molecular diagnostic test that will be able to predict kidney disease and monitor its progression in patients.

"Importantly, a companion diagnostic test that is being developed with these biomarkers may help to produce new personalized medicines, and in a shorter time frame," Richard Lipscombe, managing director of Proteomics International, said in a statement. "This could deliver optimal therapy for certain groups of patients and identify those patients where medicine would be less effective or cause side effects."

Proteomics International is a mass spectrometry-based drug discovery and contract research organization.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.